Drug General Information (ID: DDI6X2F8PC)
  Drug Name Bleomycin Drug Info Smallpox (Vaccinia) Vaccine, Live Drug Info
  Drug Type Small molecule Vaccine
  Therapeutic Class Antineoplastics Vaccine

 Mechanism of Bleomycin-Smallpox (Vaccinia) Vaccine, Live Interaction (Severity Level: Major)
     Antagonize the effect of vaccine/toxoid Click to Show/Hide Mechanism Graph
Could Not Find 2D Structure
      Drug Name Bleomycin Smallpox (Vaccinia) Vaccine, Live
      Mechanism Immunosuppressive effects Vaccine or toxoid
      Key Mechanism Factor 1
Factor Name Vaccine/toxoid
Factor Description The beneficial effects of the vaccine/toxinoid may be reduced, leading to a diminished or suboptimal immune response.
      Mechanism Description
  • Antagonize the effect of Smallpox (Vaccinia) Vaccine, Live when combined with Bleomycin 

Recommended Action
      Management Routine, nonemergency smallpox vaccination is contraindicated in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued for at least 3 months in most cases. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).

References
1 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
2 Cerner Multum, Inc. "Australian Product Information.".
3 Product Information. Dryvax (smallpox vaccine). Wyeth-Ayerst Laboratories, Philadelphia, PA.